PHP
SOPH icon

Parkman Healthcare Partners’s SOPHiA GENETICS SOPH Stock Holding History

Parkman Healthcare Partners’s Portfolio SOPH Stock Details SOPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-209,896
Closed -$1.03M – 108
2024
Q1 		$1.03M Buy
209,896
+9,899
+5% +$47.8K 0.13% 92
2023
Q4 		$942K Buy
+199,997
New +$748K 0.13% 80

Other funds holding SOPH

GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
AWA
Alta Wealth Advisors Woburn, Massachusetts $308M AUM 27.87% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
BPCE
Bank Pictet & Cie (Europe) Frankfurt Am Main, Germany $5.12B AUM 27.39% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Parkman Healthcare Partners's SOPH Position: Q2 2024 in Review

Parkman Healthcare Partners sold out of SOPHiA GENETICS (SOPH) in Q2 2024, closing a stake of 209,896 shares — an estimated $1.03M sold.

Parkman Healthcare Partners first reported a position in SOPH in Q4 2023 and held it in 2 quarters. The position peaked at $1.03M in Q1 2024. 31 funds tracked by Wall St. Rank hold SOPH as of Q2 2024.

  • Parkman Healthcare Partners reported no remaining SOPHiA GENETICS position as of Q2 2024 after selling out during the quarter.
  • Parkman Healthcare Partners sold 209,896 SOPHiA GENETICS shares in Q2 2024, an estimated $1.03M.
  • Parkman Healthcare Partners first reported a position in SOPHiA GENETICS in Q4 2023 and held it in 2 quarters.
  • Parkman Healthcare Partners's SOPHiA GENETICS position peaked at $1.03M in Q1 2024.
  • 31 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q2 2024.

Based on Parkman Healthcare Partners's 13F filing for Q2 2024, filed 14 Aug 2024.